Medicenna Therapeutics Corp
TSX:MDNA
Medicenna Therapeutics Corp
TSX:MDNA
Price:
0.62
CAD
-4.62%
Market Closed
Market Cap:
CA$48.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Medicenna Therapeutics Corp
TSX:MDNA
|
CA |
|
S
|
Shanghai Yaoji Technology Co Ltd
SZSE:002605
|
CN |
|
Exxaro Tiles Ltd
NSE:EXXARO
|
IN |
|
CARsgen Therapeutics Holdings Ltd
HKEX:2171
|
CN |
|
Blackbaud Inc
NASDAQ:BLKB
|
US |
|
K
|
Kemira Oyj
XBER:KEM
|
FI |
|
SPML Infra Ltd
NSE:SPMLINFRA
|
IN |
|
Rolex Rings Ltd
NSE:ROLEXRINGS
|
IN |
|
Myer Holdings Ltd
ASX:MYR
|
AU |
|
Inficon Holding AG
SIX:IFCN
|
CH |
|
ASGN Inc
NYSE:ASGN
|
US |
|
Procter & Gamble Health Ltd
NSE:PGHL
|
IN |
|
W
|
Winto Group (Holdings) Ltd
HKEX:8238
|
HK |
|
Shenzhen Cereals Holdings Co Ltd
SZSE:000019
|
CN |
Multiples-Based Value
The Multiples-Based Value of one
MDNA
stock under the Base Case scenario is
hidden
CAD.
Compared to the current market price of 0.62 CAD,
Medicenna Therapeutics Corp
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MDNA Multiples-Based Value
LOCKED
Multiples Across Competitors
MDNA Competitors Multiples
Medicenna Therapeutics Corp Competitors
Medicenna Therapeutics Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Medicenna Therapeutics Corp
TSX:MDNA
|
54.2m CAD | 0 | -4 | -1.8 | -1.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.2B USD | 6 | 88.2 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.4B USD | 5.9 | 20.4 | 12.7 | 15.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.4B USD | 9.3 | 28.2 | 21.2 | 22.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.5B USD | 5.6 | 17.9 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD | 3.1 | 34 | 11.3 | 14.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR | 11.3 | 36.2 | 39.3 | 40.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
